Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.

    Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

    Eligibility Criteria

    Male or female participants aged 65 to 80 years of age 
    Minimal to no cognitive/functional impairment at Screening
    Must have a study partner

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    The study involves a primary session of paper-and-pencil tasks, and a second session of a computer task, while your heart rate and brain activity is monitored. The aim of the study is to examine how signals are affected from the body to the brain.

    Eligibility Criteria

    - You are between the ages of 18-30 or 60-85

    - Free from conditions (other than amnestic mild cognitive impairment (aMCI)) which affect cognition or cardiac health

    - Fluent in the English language

    - Have normal or corrected-to-normal vision

    Recruitment End Date

  • Clinical Trial
    Online

    What is this Study about?

    Scientific evidence indicates that healthy lifestyle habits promote brain health and help prevent Alzheimer’s disease.

    Our study consists of evaluating a personalized program designed to promote healthy lifestyle habits with the goal of supporting brain health.

    This program, called Luci, is available as an online platform with virtual guidance from an advisor. Its purpose is to help participants change their lifestyle habits. It focuses on three areas: physical activity, healthy eating, and intellectual stimulation.

    The aim of this study is to determine whether our program helps improve lifestyle habits in these three areas, along with other indicators linked to brain health.

    Eligibility Criteria

    You are eligible to participate if you:

    • Are aged between 50 and 75 years of age

    • Have not been diagnosed with a cognitive disorder, such as Alzheimer’s disease

    • Wish to adopt healthy lifestyle habits in at least one of the following domains: physical activity, healthy eating, and intellectual stimulation

    • Have access to a tablet or computer with an internet connection

    • Are able to speak English or French

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    CAN-PROTECT is a Canada-wide online study recruiting participants and caregivers of persons with dementia to explore how lifestyle, background, and caretaking factors affect our health, quality of life, cognition, behaviour, and function as we age. CAN-PROTECT data will be analyzed and jointly published by the University of Calgary in partnership with the University of Exeter.

    Eligibility Criteria

    - Age 18 years or older

    - Reside in Canada

    - Have access to a computer/touchscreen device

    - Can provide informed consent

    - Do not have a diagnosis of dementia

    - Additionally, we are enrolling participants who have previously or currently care for persons with dementia for caregiver-specific assessments

    - Ability to speak English

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date